Business
Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease
– SL-325 is a potentially first-in-class DR3 antagonist antibody being developed for the treatment of Inflammatory Bowel Disease (IBD) and other inflammatory and immune-mediated diseases – – The Company is on track to dose the first participant in its Phase 1 SL-325 clinical trial in healthy volunteers in Q3 2025 – – Current cash and cash equivalents, plus the anticipated aggregate proceeds of up to $103 million from recent private placement, assuming full exercise of common stock warrants, expe
About this update from Shattuck Labs, Inc.
[{"type":"image","alt":"Shattuck Labs, Inc.","displaySize":"","headline":null,"caption":"Shattuck Labs, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":69,"url":"https://media.zenfs.com/en/globenewswire.com/b5ea3fb4ff3f25592a62a57f48a4f2e8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/o_.4r1lpCFq8StfajNT2qg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk3O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/b5ea3fb4ff3f25592a62a57f48a4f2e8","width":300,"height":69}},"lazy":false},{"type":"text","content":"– SL-325 is a potentially first-in-class DR3 antagonist antibody being developed for the treatment of Inflammatory Bowel Disease (IBD) and other inflammatory and immune-mediated diseases –","length":193,"tagName":"p"},{"type":"text","content":"– The Company is on track to dose the first participant in its Phase 1 SL-325 clinical trial in healthy volunteers in Q3 2025 –","length":127,"tagName":"p"},{"type":"text","content":"– Current cash and cash equivalents, plus the anticipated aggregate proceeds of up to $103 million from recent private placement, assuming full exercise of common stock warrants, expected to fund operations into 2029 –","length":218,"tagName":"p"},{"type":"text","content":"AUSTIN, TX and DURHAM, NC, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-mediated diseases, today announced that the Company’s Investigational New Drug (IND) application submitted to the U.S. Food and Drug Administration (FDA) for SL-325 for the treatment of inflammatory bowel disease is in effect. SL-325, a potentially first-in-class DR3 blocking antibody, is a fully Fc-silenced humanized immunoglobulin G monoclonal antibody, demonstrated high-affinity binding to human DR3 and potent inhibition of TL1A binding to DR3 in preclinical studies, and a favorable safety profile in non-human primate studies.","length":850,"tagName":"p"},{"type":"text","content":"Dosing of the first participant is expected this quarter, and enrollment of the Phase 1 clinical trial is expected to be completed in the second quarter of 2026. The Phase 1 clinical trial is a randomized, double-blind, placebo-co...